Skip to main content

Biogen buys a brain disorder drug for $217 million, but needs to go bigger, analyst says

Massachusetts-based Biogen reported fourth-quarter revenue of $3.31 billion, above the $3.1 billion expected from analysts polled by Thomson Reuters.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.